TGFB1 and cancer: As stated above, therapies targeting the PDGF, TGF-β, and FGF pathways in cancer cells have undergone extensive clinical trials, with several approved in other cancers, and even some have been tested in GEP-NETs, such as Sutent®, Votrient®, and Cabometyx®.